ELVN Stock Forecast & Price Target

Enliven Therapeutics is viewed favorably because ELVN-001 has moved from Phase 1 de-risking into pivotal execution, with FDA alignment on the final Phase 3 ENABLE-2 design in 2L+ CML and a planned start by YE26, while a 1L CML Phase 3 is planned for early 2028. The investment case is strengthened by the drug’s compelling early efficacy and tolerability, including a 61% overall MMR by 24 weeks in Phase 1b at EHA 2026, which compares favorably with bosutinib and asciminib in ASCEMBL and supports management’s view that a >10% MMR improvement is achievable. Financially, the company ended 3Q26 with $884M in cash and equivalents, expected to fund operations into 2030, while 3Q R&D was $28.0M and G&A was $8.0M, leaving it well-capitalized to advance both Phase 3 programs.

Enliven Therapeutics is exposed to substantial clinical, regulatory, and commercialization risk because its value depends on a narrow pipeline of early-stage small-molecule assets, including ELVN-001 for BCR-ABL-driven CML and ELVN-002 for HER2 mutations. Any R&D or regulatory setback could materially delay or derail development, while competitive pressure from new entrants could erode future market opportunity and limit adoption even if the programs succeed. The company also faces the risk of lower-than-expected product sales and dilutive financing, which could weaken shareholder returns and signal dependence on external capital before meaningful commercial traction is established.